Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
FCM MM Holdings sent a letter to MindMed’s (NASDAQ:MNMD) board of directors calling on them to adopt a new strategic plan to "turn the company around.”
The note begins with a provocative statement: “We have seen the value of our investments in MindMed plummet as the stock has fallen from its highs of around $5.77 to $0.70 per share,” and then goes on to express investors’ concern “about the company’s strategic direction.”
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The group represented by FCM investments believes MindMed’s management has underperformed partly due to dividing its attention “among too many different projects” resulting in a lack of focus on the company’s core drugs: MM-110 (18-MC) and MM-120 (LSD).
FCM’s detailed scheme notes that it is confident in MindMed’s ability to “significantly reduce” the R&D steps for both proprietary drugs to reach the market in four years, rather than seven or eight, by re-classifying the Phase 2b study on MM-120 to a Phase 3 study.
The proposal also calls for MindMed to reduce cash burn for approximately 50%, going from $45 million per year to under $25 million. That is, according to FCM’s letter, the unnecessary and dilutive at-the-money offering should be eliminated.
The FCM fund is managed by cofounder Dr. Scott Freeman, who was MindMed’s chief medical officer in the 2019-2020 period. FCM represents an overall investment of almost 5.6% of the company’s shares outstanding.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
Scott Freeman was Chief Medical Officer (CMO) of MindMed for a little over a year (Spring 2019 - Summer 2020), moving over from Savant HWP which was acquired by MindMed for its 18-MC program.
— Psychedelic Alpha (@Psyched_Alpha) August 11, 2022
Here's Scott on MindMed's website back in March 2020. pic.twitter.com/o0S6btBrKE
In numbers, Dr. Freeman's investment in MindMed is claimed to be in excess of 19 million shares or 4.51% of MindMed's outstanding shares. The other signee is Chad Boulanger who holds an investment in over four million shares or equivalent 1% of outstanding shares.
The letter concludes by calling for MindMed’s reply before August 31, 2022, and proposing Dr. Freeman's incorporation onto the board of directors “to unlock the company’s full potential.”
Photo by Álvaro Serrano on Unsplash
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.